Delta 9 Cannabis Inc
TSX:DN
Delta 9 Cannabis Inc
TSX:DN
Price:
0.01
CAD
Market Cap:
CA$3.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Delta 9 Cannabis Inc
TSX:DN
|
CA |
|
Hulic Co Ltd
TSE:3003
|
JP |
|
Park Ohio Holdings Corp
NASDAQ:PKOH
|
US |
|
SigmaTron International Inc
NASDAQ:SGMA
|
US |
|
Argo Blockchain PLC
LSE:ARB
|
UK |
|
G
|
Global Helium Corp.
CNSX:HECO
|
CA |
|
Birchcliff Energy Ltd
TSX:BIR
|
CA |
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
TW |
|
Hiday Hidaka Corp
TSE:7611
|
JP |
|
Guided Therapeutics Inc
OTC:GTHP
|
US |
|
Vince Holding Corp
NYSE:VNCE
|
US |
|
GS Global Corp
KRX:001250
|
KR |
|
D
|
Denis Chem Lab Ltd
BSE:537536
|
IN |
|
N
|
Nft Ltd
AMEX:MI
|
HK |
|
V
|
Vast Renewables Ltd
NASDAQ:VSTE
|
AU |
|
D
|
Digihost Technology Inc
XTSX:DGHI
|
CA |
|
Joyas International Holdings Ltd
SGX:E9L
|
HK |
|
E
|
Everbright Digital Holding Ltd
NASDAQ:EDHL
|
HK |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of DN.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DN
Multiples-Based Value
Not Available
Multiples Across Competitors
DN Competitors Multiples
Delta 9 Cannabis Inc Competitors
Delta 9 Cannabis Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Delta 9 Cannabis Inc
TSX:DN
|
3.5m CAD | 0 | -0.2 | -36.3 | -2.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
855.1B USD | 13.1 | 41.3 | 28 | 29.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.7B USD | 5.8 | 26.7 | 17.1 | 21.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.6 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
229B GBP | 5.2 | 29.8 | 16.5 | 23.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.1B CHF | 5 | 20.2 | 12.5 | 16.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
291.8B USD | 4.4 | 15.6 | 9.7 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.7 | 11.1 | 8.2 | 9.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.6B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
86.8B GBP | 2.6 | 15.1 | 8.2 | 10.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
